Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 288,814 shares, a growth of 29.0% from the January 15th total of 223,806 shares. Based on an average daily volume of 61,235 shares, the short-interest ratio is presently 4.7 days. Currently, 0.8% of the shares of the stock are sold short. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 61,235 shares, the short-interest ratio is presently 4.7 days.

Nyxoah Trading Up 1.1%

NASDAQ NYXH traded up $0.05 during trading hours on Monday, hitting $4.43. The company’s stock had a trading volume of 20,729 shares, compared to its average volume of 46,861. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.40. Nyxoah has a twelve month low of $4.10 and a twelve month high of $11.87. The firm has a market capitalization of $150.89 million, a P/E ratio of -1.78 and a beta of 1.55. The stock has a fifty day moving average of $4.79 and a 200 day moving average of $5.32.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Friday, November 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The company had revenue of $2.31 million for the quarter, compared to analyst estimates of $1.95 million. Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%. Equities research analysts forecast that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Trading of Nyxoah

A number of institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. boosted its holdings in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares during the period. Bank of America Corp DE increased its stake in shares of Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the period. Citadel Advisors LLC acquired a new stake in Nyxoah during the 3rd quarter worth approximately $98,000. Deutsche Bank AG boosted its stake in Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the period. Finally, Shay Capital LLC acquired a new position in Nyxoah in the 2nd quarter valued at $374,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NYXH shares. Stifel Nicolaus reduced their price target on shares of Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Piper Sandler restated an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nyxoah presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.